Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5yrs. Results: 87.4% mean reduction in […]readmore
Tags : HELP Study
Shots: The P-III HELP OLE study evaluating the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5 yrs. Results: 87.4% mean reduction […]readmore
Shots: The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg, SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 […]readmore